Understanding Primary Progressive MS and Treatment Challenges
Primary progressive multiple sclerosis (PPMS) is a form of MS where symptoms worsen steadily over time, with no relapses or remissions. Unlike relapsing-progressive MS, PPMS lacks approved PBS-listed treatments in Australia, leaving many patients with limited options. Current therapies like ocrelizumab, while effective for some forms of MS, are not yet accessible through Australia’s public funding system. This gap underscores the urgency for innovative treatments that can address the progressive nature of PPMS.
What is Fenebrutinib and How Does It Work?
Fenebrutinib belongs to a class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors. BTK plays a key role in immune cell signaling, particularly in B cells and brain-resident microglia—cells implicated in MS-related damage. By selectively inhibiting BTK, fenebrutinib aims to reduce harmful immune activity in the central nervous system. Unlike permanent BTK inhibitors like evobrutinib, fenebrutinib binds reversibly, potentially offering a safer profile while maintaining efficacy.
The FENtrepid Trial: A New Hope for PPMS
The FENtrepid Phase 3 trial compared fenebrutinib to ocrelizumab in people with PPMS. As a non-inferiority study, its goal was to prove fenebrutinib was not worse than the existing treatment. Preliminary results from November 2025 showed fenebrutinib matched ocrelizumab in delaying composite disability progression over 120 weeks. More detailed analysis in February 2026 revealed stronger effects in preserving arm function, reducing the risk of worsening by 26% compared to ocrelizumab.
Key Findings: Arm Function and Overall Efficacy
The trial’s most significant result was fenebrutinib’s impact on upper limb function, measured by the nine-hole peg test (9HPT). This improvement suggests the drug may better address daily mobility challenges faced by PPMS patients. When combined with expanded disability status scale (EDSS) scores, fenebrutinib showed a 22% reduction in disability progression risk. While the trial was not designed to prove superiority, these trends indicate potential advantages over current therapies.
Safety Profile: Similar to Ocrelizumab with Notable Differences
Fenebrutinib’s safety profile closely mirrored ocrelizumab’s, with common side effects like infections, nausea, and bleeding occurring at similar rates. However, fenebrutinib was associated with higher rates of elevated liver enzymes (13.3% vs. 2.9%), though these were temporary and resolved upon discontinuation. No severe liver injuries were reported, addressing a safety concern seen with other BTK inhibitors. Serious adverse events and treatment discontinuation rates were also comparable.
Implications for PPMS Patients in Australia and Beyond
For Australians, the FENtrepid results offer hope for a potential second treatment option for PPMS. If approved, fenebrutinib could address the lack of PBS-listed therapies, improving access for those who cannot afford ocrelizumab. Globally, the drug’s oral formulation may enhance adherence compared to injectable therapies like ocrelizumab. However, regulatory approval is pending, with submissions expected by mid-2026.
What This Means for Future MS Care
The success of fenebrutinib in PPMS trials marks a milestone after over a decade without new PPMS therapies. It highlights the potential of BTK inhibitors to target disease mechanisms more precisely. Ongoing research, including the FENhance 1 trial for relapsing MS, could expand its applicability. For patients, staying informed about regulatory updates and discussing treatment options with neurologists will be critical.
Medical Disclaimer
This article provides general information about fenebrutinib and PPMS treatment. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before making decisions about MS management or new therapies.
